68
Participants
Start Date
July 23, 2018
Primary Completion Date
January 17, 2019
Study Completion Date
January 17, 2019
Semaglutide, 0.5 mg/mL
A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
Semaglutide, 1.0 mg/mL
A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
Semaglutide, 1.34 mg/mL
A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
Semaglutide, 2.0 mg/mL
A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
DV3372, 0.5 mg/mL
DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
DV3372, 1.0 mg/mL
DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
PDS290
PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
NovoPen®4
NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
Novo Nordisk Investigational Site, Neuss
Novo Nordisk Investigational Site, Mainz
Lead Sponsor
Novo Nordisk A/S
INDUSTRY